Johnson & Johnson (JNJ)
177.40
+0.00 (0.00%)
NYSE · Last Trade: Sep 16th, 4:46 AM EDT
Detailed Quote
Previous Close | 177.40 |
---|---|
Open | - |
Bid | 177.03 |
Ask | 177.93 |
Day's Range | N/A - N/A |
52 Week Range | 140.68 - 181.16 |
Volume | 458 |
Market Cap | 466.33B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (2.93%) |
1 Month Average Volume | 7,698,479 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Dividend-paying growth stocks and covered call ETFs provide opportunities to generate income even in a declining stock market.
Via The Motley Fool · September 16, 2025
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drugstocktwits.com
Via Stocktwits · September 15, 2025
These three companies may have what it takes to continue to build on their strong history of dividend payments even if the economy continues to sour.
Via MarketBeat · September 15, 2025
The United States economy is facing an increasingly complex and concerning confluence of risk factors, raising the specter of a looming recession. A deteriorating labor market, persistently high inflation, and the ongoing, disruptive impact of trade tariffs are interacting in ways that significantly elevate economic uncertainty for businesses, consumers, and
Via MarketMinute · September 15, 2025
As the global economy marches into 2025, it finds itself at a critical juncture, balancing the promise of moderate growth against the persistent shadows of tenacious inflation, geopolitical instability, and evolving labor market dynamics. This year is set to be defined by a complex interplay of forces that will shape
Via MarketMinute · September 15, 2025
The U.S. economy finds itself at a crossroads, with leading financial institutions and economic forecasters presenting a varied, yet generally cautious, outlook on the probability of a recession. From machine learning algorithms to traditional yield curve models, the consensus is that while a severe downturn isn't a foregone conclusion,
Via MarketMinute · September 15, 2025
The latest U.S. employment report for August 2025 has sent a palpable chill through financial markets and economic forecasts, confirming a significant deceleration in the nation's labor market. Following a rare job contraction in June—the first monthly decline in nonfarm jobs since December 2020—the unemployment rate has
Via MarketMinute · September 15, 2025
Financial markets are currently on edge, grappling with the looming possibility of a significant shock: an unexpected decision by the Federal Reserve to forgo a widely anticipated interest rate cut in September 2025. This deviation from market consensus, which largely projects a 25-basis-point reduction, could trigger a sharp negative reaction
Via MarketMinute · September 15, 2025
As autumn leaves begin to fall, a familiar chill often descends upon the financial markets, not just in temperature but in investor sentiment. September has historically earned a notorious reputation among traders and analysts as the weakest month for equities, a phenomenon widely dubbed the "September Effect." This recurring statistical
Via MarketMinute · September 15, 2025
The S&P 500's current forward price-to-earnings (P/E) ratio, hovering around 22x, has ignited a fervent debate across financial markets. This elevated valuation metric, significantly above historical averages, is prompting investors and analysts to question whether the market is perched precariously on a speculative bubble or if a new
Via MarketMinute · September 15, 2025
The answer might surprise you.
Via The Motley Fool · September 15, 2025
The global financial landscape is currently grappling with a potent concoction of heightened market instability, pervasive policy uncertainty, and an escalating array of geopolitical events. These formidable forces are collectively reshaping investment strategies and underscoring the critical need for robust diversification and strategic hedging within portfolios. As investors navigate these
Via MarketMinute · September 12, 2025
Global financial markets in 2025 are navigating a complex landscape shaped by persistently high, or "sticky," inflation and the increasingly cautious stance of major central banks regarding interest rate adjustments. Despite initial hopes for a swift return to pre-pandemic price stability, inflation, particularly in the services sector and fueled by
Via MarketMinute · September 12, 2025
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Via MarketMinute · September 12, 2025
In an era defined by persistent market volatility and an ongoing search for reliable income streams, a historically potent, yet sometimes overlooked, options strategy is experiencing a significant resurgence: the covered call. As global financial markets navigate a landscape shaped by inflation concerns, fluctuating interest rates, and geopolitical uncertainties, investors
Via MarketMinute · September 12, 2025
In an ever-fluctuating financial landscape, where market volatility and economic uncertainties often dominate headlines, the timeless appeal of dividend-paying stocks continues to shine as a classic and dependable strategy for investors. Particularly, an investment focus on established blue-chip companies, renowned for their stability and financial fortitude, offers a compelling pathway
Via MarketMinute · September 12, 2025
The financial markets are on the cusp of a significant "Great Rebalancing," with small-cap and value stocks emerging from a prolonged period of underperformance to challenge the dominance of mega-cap technology and growth companies. As the Federal Reserve signals an increasingly dovish stance and the anticipation of interest rate cuts
Via MarketMinute · September 12, 2025
Johnson & Johnson investors focus on its pharma strength, legal strategy shift, and growth in medical devices amid sector challenges.
Via Benzinga · September 12, 2025
The global economy is currently navigating a treacherous landscape, marked by a confluence of significant headwinds that are increasingly dictating the Federal Reserve's monetary policy path. Intensifying geopolitical tensions, a palpable resurgence of protectionist trade policies, stubbornly persistent inflationary pressures, and a general deceleration in global economic growth are the
Via MarketMinute · September 11, 2025
These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners.
Via The Motley Fool · September 11, 2025
The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for patients, avoiding surgery.
Via Benzinga · September 10, 2025
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high unemployment, and persistent inflation. This peculiar confluence, which defies traditional economic models, is sending ripples of concern through financial markets and
Via MarketMinute · September 10, 2025
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade tensions, persistent policy uncertainty, and tighter financial conditions is converging to paint a picture of decelerated growth, raising concerns about job
Via MarketMinute · September 10, 2025
Concerns are escalating over the Federal Reserve's long-standing independence as political pressure intensifies, raising fundamental questions about the future of U.S. monetary policy and its implications for financial markets. Recent actions from the executive branch, including an attempted dismissal of a sitting Fed governor and the nomination of individuals
Via MarketMinute · September 10, 2025
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder.
Via Benzinga · September 10, 2025